Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Respir Med ; 105(1): 137-42, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21041073

RESUMEN

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so early diagnosis of MPM is very important. Vascular endothelial growth factor (VEGF), a potent mitogen for the vascular endothelium, is also known to be an autocrine growth factor for MPM. Here, we investigated the pleural effusion VEGF levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion. METHODS: The pleural effusion VEGF concentrations were measured in 46 MPM patients and 45 individuals with non-MPM individuals (25 individuals with non-malignant pleural effusions, and 20 individuals with lung cancer involving malignant pleural effusion). RESULTS: We demonstrated that patients with MPM had significantly higher pleural effusion VEGF levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage MPM patients. The difference in overall survival between the groups with pleural effusion VEGF levels lower and higher than the assumed cut-off of 2000pg/ml was significant. CONCLUSIONS: Our data suggest that the pleural effusion VEGF concentration could be useful as an aid for the diagnosis of MPM and as a prognostic factor.


Asunto(s)
Biomarcadores de Tumor/análisis , Mesotelioma/metabolismo , Derrame Pleural/metabolismo , Neoplasias Pleurales/metabolismo , Factor A de Crecimiento Endotelial Vascular/análisis , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Mesotelioma/mortalidad , Neoplasias Pleurales/mortalidad , Pronóstico , Tasa de Supervivencia
2.
J Thorac Oncol ; 5(4): 479-83, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20357617

RESUMEN

INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so diagnosing MPM early is very important. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for MPM. Here, we investigated the serum levels of VEGF in patients with MPM in comparison with a population that had been exposed to asbestos without developing MPM. METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure. RESULTS: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM. The difference in overall survival between the groups with VEGF serum levels lower and higher than the assumed cutoff of 460 pg/ml was significant. CONCLUSIONS: Our data suggest that the VEGF serum concentration could be a useful marker for screening MPM among asbestos-exposed individuals and as a prognostic factor.


Asunto(s)
Asbestosis/sangre , Biomarcadores de Tumor/sangre , Mesotelioma/sangre , Neoplasias Pleurales/sangre , Factor A de Crecimiento Endotelial Vascular/sangre , Anciano , Amianto/efectos adversos , Asbestosis/patología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Mesotelioma/patología , Estadificación de Neoplasias , Exposición Profesional , Neoplasias Pleurales/patología , Pronóstico , Curva ROC , Tasa de Supervivencia
3.
Intern Med ; 48(24): 2145-9, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-20009410

RESUMEN

We report a case of cytomegalovirus (CMV) pneumonitis that presented as a cavitary lung lesion in a patient with systemic lupus erythematosus receiving immunosuppressive treatment. The lesion was confirmed by positive polymerase chain reaction (PCR) for CMV in bronchoalveolar lavage fluid (BALF) and CMV antigenemia. PCR for CMV in BALF was demonstrated to be useful for the diagnosis of CMV pneumonitis on the basis of high sensitivity and specificity. After initiating ganciclovir, the lesion gradually regressed. A cavitary lung lesion associated with CMV is extremely rare. This presentation suggests that the differential diagnosis of cavitary lung lesion in immunocompromised individuals should include CMV.


Asunto(s)
Infecciones por Citomegalovirus/diagnóstico por imagen , Infecciones por Citomegalovirus/inmunología , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Antivirales/uso terapéutico , Líquido del Lavado Bronquioalveolar/virología , Infecciones por Citomegalovirus/tratamiento farmacológico , Femenino , Humanos , Persona de Mediana Edad , Tomografía Computarizada por Rayos X
4.
Nihon Kokyuki Gakkai Zasshi ; 45(9): 720-5, 2007 Sep.
Artículo en Japonés | MEDLINE | ID: mdl-17929476

RESUMEN

A 66-year-old woman was admitted due to right cervical lymphadenopathy and an abnormal chest radiograph. Acid-fast bacilli smear of fine needle aspiration from a right cervical lymph node was positive. Histopathological examination of the specimen obtained by percutaneous right cervical lymph node biopsy showed necrotizing epithelioid granulomas and no malignant cells. Therefore, right cervical tuberculous lymphadenitis was diagnosed. Partial lung resection of the right S4 was carried out by video-assisted thoracoscopic surgery and primary lung cancer was diagnosed. To our knowledge, there has been no previous report of both primary lung cancer and cervical tuberculous lymphadenitis being present at the time of the first examination. We report this very rare case.


Asunto(s)
Adenocarcinoma/complicaciones , Neoplasias Pulmonares/complicaciones , Tuberculosis Ganglionar/complicaciones , Adenocarcinoma/secundario , Adenocarcinoma/cirugía , Anciano , Terapia Combinada , Femenino , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Ganglios Linfáticos/patología , Metástasis Linfática , Cirugía Torácica Asistida por Video
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...